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Background: Carapa guianensis is a cultivable tree used by traditional health practitioners in the Amazon region to
treat several diseases and particularly symptoms related to malaria. Abundant residual pressed seed material (RPSM)
results as a by-product of carapa or andiroba oil production. The objective of this study was to evaluate the in vitro
and in vivo anti-malarial activity and cytotoxicity of limonoids isolated from C. guaianensis RPSM.
Methods: 6α-acetoxyepoxyazadiradione (1), andirobin (2), 6α-acetoxygedunin (3) and 7-deacetoxy-7-oxogedunin (4)
(all isolated from RPSM using extraction and chromatography techniques) and 6α-hydroxy-deacetylgedunin (5)
(prepared from 3) were evaluated using the micro test on the multi-drug-resistant Plasmodium falciparum K1 strain.
The efficacy of limonoids 3 and 4 was then evaluated orally and subcutaneously in BALB/c mice infected with
chloroquine-sensitive Plasmodium berghei NK65 strain in the 4-day suppressive test.
Results: In vitro, limonoids 1-5 exhibited median inhibition concentrations (IC50) of 20.7-5.0 μM, respectively. In
general, these limonoids were not toxic to normal cells (MRC-5 human fibroblasts). In vivo, 3 was more active than
4. At oral doses of 50 and 100 mg/kg/day, 3 suppressed parasitaemia versus untreated controls by 40 and 66%,
respectively, evidencing a clear dose–response.
Conclusion: 6α-acetoxygedunin is an abundant natural product present in C. guianensis residual seed materials that
exhibits significant in vivo anti-malarial properties.
Keywords: Malaria, 6α-acetoxyepoxyazadiradione, 6α-acetoxygedunin, Andirobin, 7-deacetoxy-7-oxogedunin,
6α-hydroxy-deacetylgedunin, Plasmodium falciparum, Plasmodium berghei, Human fibroblasts, AntiplasmodialBackground
In 2010, there were an estimated 219 million cases of mal-
aria infection resulting in 660,000 deaths worldwide [1].
Chloroquine-resistant (CQR) Plasmodium falciparum is
now widespread and there are growing numbers of reports
of CQR Plasmodium vivax worldwide. In recent years,
artemisinin-based combined therapy (ACT) has been in-
troduced as the first-line of treatment for P. falciparum* Correspondence: ampohlit@inpa.gov.br
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unless otherwise stated.and for the treatment of CQR P. vivax. However, reports
of P. falciparum exhibiting resistance to artemisinin deriv-
atives in four Southeast Asian countries, and resistance to
ACT in a region of Cambodia are increasing the interest
in lead compounds for the development of a new gener-
ation of anti-malarial drugs [1-4].
Natural products are the direct or indirect sources of
most of the drugs introduced in the past 30 years [5].
Natural products from plants are a rich source of lead
compounds for the development of new drugs against
protozoan parasitic diseases such as malaria [6-9]. Quinine
[10] and artemisinin are potent antimalarial natural prod-
ucts from plants. Further development gave rise toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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that form the basis of ACT. Today, artemisinin derivatives
(e.g. sodium artesunate, arteether, dihydroartemisinin) and
quinolines (e.g. chloroquine, primaquine) are the basis of
malaria treatment worldwide. The Amazon region has a
rich tradition of plant use for the treatment of malaria and
a number of natural products have been isolated and
semi-synthetic derivatives prepared exhibiting important
in vitro and in vivo anti-malarial properties [11].
Andiroba (Carapa guianensis) belongs to the Meliaceae
family of plants. It is found in western India, South Africa
and South America and is readily cultivated. Its trees can
reach heights of 30 m and can produce 50 to 200 kg of
seeds per year [12]. Andiroba oil, or carapa oil, as it is also
known, is obtained from the seeds and has several uses in
traditional medicine including the treatment of malaria
[12-16]. A common method for obtaining andiroba oil
begins by chopping the seeds into small pieces and then
cooking on a fire-heated hot plate at a temperature of cerca
90°C. Then, the cooked seed meal is mechanically pressed
to obtain the oil. This process generates a large quantity
of residual seed material as a by-product that contains
many bioactive constituents, including limonoids [13]. The
following limonoids have been previously isolated from
andiroba oil and are present in residual seed materials
(Figure 1): 6α-acetoxyepoxyazaradione (1), andirobin (2),
6α-acetoxygedunin (3), 7-deacetoxy-7-oxogedunin (4), gedu-
nin (6), 6α-hydroxygedunin (8), 1, 2-dihydro-3β-hydroxy-7-
deacetoxy-7-oxogedunin, 17β-hydroxyazadiradione, methyl
angolensate and xilocenin K [15,17,18].
Andiroba oil exhibits in vitro activity against P. falcip-
arum. At concentrations of 8.2 μg/mL of the oil and
3.1 μg/mL of a limonoid-rich fraction obtained from
this oil, 100% inhibition of the W2 strain of P. falcip-
arum was observed after 24 h. Also, andiroba oil and a
limonoid-rich fraction exhibited IC50 values of 9.4 and
2.4 μg/mL, respectively, after 48 h against the Dd2
strain of P. falciparum [19].
In a recent study, 16 limonoid components of the flowers
of Carapa guianensis were isolated and nine of these com-
ponents were tested for in vitro inhibitory activity against
the FCR-3 strain of P. falciparum. Gedunin (6) and
structurally-related limonoids 3, 4, 7 and 8 (Figure 1) ex-
hibited the most in vitro inhibition (IC50 2.5-2.8 μM) [20].
Despite the in vitro anti-plasmodial potential of gedunin
and previous studies on its natural and semi-synthetic de-
rivatives [20-24], in vivo anti-malarial data for gedunin-type
limonoids in the literature are limited to gedunin itself
and a semi-synthetic derivative of gedunin, 7-deacetyl-7O-
methyl-gedunin (10) [22,23]. These and other reasons
prompted us to publish the present work on the in vitro
anti-plasmodial activity of limonoids 1-4 isolated from C.
guianensis and a semi-synthetic derivative 5 (Figure 1) and
the in vivo anti-malarial activity of 3 and 4 in infected mice.Methods
Collection of andiroba seeds and production of residual
pressed seed material (RPSM).
Collection took place on the morning of June 6, 2011.
Carapa guiananesis seeds were collected at the National
Institute for Amazon Research’s (INPA) Adolpho Ducke
Forest Reserve located in Manaus, Amazonas State, Brazil
from the areas beneath two trees identified by voucher
specimens deposited previously in the INPA Herbarium
under the accession numbers 192615 and 178658 [25].
Triage was performed by discarding perforated, marred
and/or moldy seeds. In the municipality of Manaquiri,
64 km from Manaus, extraction of the oil was performed
by first triturating the seeds (fresh weight 10 kg), heating
(partially drying) the resulting ground seeds on a hot plate,
followed by pressing the dried, ground seeds at room
temperature in an industrial press. This last step led to the
RPSM (5.3 kg) and crude andiroba oil (500 mL) contain-
ing suspended matter. After centrifuging, transparent,
slightly yellow andiroba oil was obtained as an upper layer
and the dark-coloured suspended matter (330 mg) was
concentrated in the lower layer.
Extraction and isolation
Residual pressed seed material (RPSM) (106.2 g) was
continuously extracted (3 × 6 h) with acetone (300 mL)
in a soxhlet apparatus. The combined acetone extracts
were concentrated on a rotary evaporator and then
freeze-dried. Dry acetone extract was dissolved in a mix-
ture of 90:10 methanol/water (100 mL) and partitioned
with hexanes (3 × 100 mL). The phases were separated
and water was added to the methanol/water phase until
a composition of 70:30 was reached. The latter was parti-
tioned with chloroform (3 × 150 mL) and the combined
chloroform fractions were totally evaporated. Column
chromatography (CC) was performed on the combined
chloroform fraction using silica gel 60 (particle size: 63-
200 μm, column: d × h = 5.5 × 38.5 cm) and a gradient of
hexanes and ethyl acetate (90:10, then 80:20), chloroform
and ethyl acetate (90:10) and finally methanol (100%). The
40 chromatographic fractions obtained were analyzed by
thin-layer chromatography (TLC) and combined into 12
fractions. Fraction 4 was further separated by CC on silica
gel 60 (40-63 μm, d × h = 2.3 × 17 cm). Chloroform
(100%) was used as eluent and 6α-acetoxyazadiradione
(1) (105 mg) and andirobin (2) (24.2 mg) were obtained
in pure fractions. Fraction 2 was further separated
by CC on silica gel 60 (63-200 μm, d × h = 2.3 × 17 cm)
and eluted with a gradient of hexanes/chloroform/ethyl
acetate (56:33:11, 33:53:14, 20:50:30) to obtain 60 frac-
tions that were combined into 33 fractions based on the
similarity of their TLC profiles and 6α-acetoxygedunin
(3) was obtained as a pure fraction (73.2 mg). A neigh-
boring fraction was further purified by preparative TLC
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Figure 1 Structures of limonoids isolated from Carapa guianensis and their semi-synthetic derivatives. 6α-acetoxyepoxyazadiradione (1),
andirobin (2), 6α-acetoxygedunin (3) and 7-deacetoxy-7-oxogedunin (4) were isolated herein from the residual seed material of C. guianensis.
Semi-synthetic derivative 6α-hydroxydeacetylgedunin (5) was prepared herein. Gedunin (6), andirolide H (7), 6α-hydroxygedunin (8),
7-deacetylgedunin (9) and 7-deacetyl-7-O-methylgedunin (10) were reported by others as indicated in the text.
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lation of more 3 (44.7 mg) and 7-deacetoxy-7-oxogedunin
(4) (59.8 mg). Larger quantities of 3 and 4 for in vivo stud-
ies were available by extracting RPSM (1.1 kg) and liquid-
liquid partitioning of the resulting extract (603.3 g) as
described above followed by CC on the chloroform
fraction (23.4 g) using silica gel 60 (40-63 μm, d × h =
5.5 × 40 cm) and eluted with hexanes/dichloromethane
(40:60, then 20:80) and hexanes/dichloromethane/ethyl
acetate (33:53:14, then 20:50:30), to yield a fraction
containing 3 and 4 (1.9 g). CC on this fraction using
silica gel 60 (40-63 μm, d × h = 4.3 × 30.5 cm) and elu-
tion with 97:3, 95:5 and then 90:10 mixtures of solvents
A (95:5 hexanes/chloroform) and B (1:1 ether/butanol)
yielded 3 combined fractions after TLC analysis. Fractions
1 and 3 contained pure 3 (325 mg) and 4 (395 mg), re-
spectively. Fraction 2 (150 mg) was separated by prepara-
tive TLC using hexanes/ether/butanol (82:9:9) leading to
isolation of more 3 and 4 (overall yields were 402 and
452 mg, respectively).Deacetylation of 3
This was carried out by dissolving 3 (40.5 mg, 75 μmol) in
high performance liquid chromatography (HPLC) grade
methanol (2.7 mL), adding anhydrous potassium carbon-
ate (80 mg, 0.6 mmol) and magnetically stirring the result-
ing mixture at room temperature for 24 h. The reaction
mixture was transferred using washings with chloroform
(3 × 2 mL) and the resulting mixture was dried with satu-
rated sodium chloride solution, then anhydrous sodium
sulfate and then the drying agent was removed by filtra-
tion. The filtrate was totally evaporated and the resulting
residue was recrystallized from HPLC grade methanol to
obtain the diol product 6α-hydroxydeacetylgedunin (5)
(12.8 mg, 28 μmol, 37%).
Spectral analysis
High-resolution mass spectra (HRMS, Waters, Xevo Model)
were obtained by direct infusion of each pure com-
pound dissolved in methanol/water. Nuclear magnetic
resonance (NMR) spectra were obtained of each pure
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600 MHz and 400 MHz. HRMS and full 1H and 13C
NMR data on all isolated and prepared compounds are
provided as Additional file 1.
In vitro anti-plasmodial assay
In vitro cultures of the K1 strain of P. falciparum were
established using A + type blood cells and Roswell Park
Memorial Institute (RPMI 1640) culture medium enriched
with 10% plasma in accordance with the Trager and Jen-
sen procedure [26]. The in vitro inhibition of the growth
of P. falciparum K1 from these cultures by limonoids 1-4
and derivative 5 was evaluated as described previously
[27]. Briefly, this procedure involved preparing 5 mg/mL
stock solutions of each compound in dimethyl sulfoxide
(DMSO). The stock solutions were diluted to provide
test solutions having concentrations in the range 0.13-
100 μg/mL. Test solutions were transferred to 96-well
test plates containing parasitized red blood cells with
initial 2% haematocrit and 1% parasitaemia. Each sample
was evaluated in duplicate and the test plate was incu-
bated for 48 h at 37°C. After incubation, quantification of
parasites was achieved by optical microscopy on blood
smears from each well [27].
Animals and ethical approval
Adult BALB/c mice (22 ± 3 g weight) were used for the
in vivo anti-malarial tests and received water and food ad
libitum. In vivo tests were performed using ‘Guidelines for
Ethical Conduct in The Care and Use of Animals of the
National Institute for Amazon Research (INPA)’. This
work was authorized by INPA’s Commission of Ethics for
the Use of Animals (CEUA 062/2012).
In vivo anti-malarial assay
Limonoids 3 and 4 were assayed for in vivo anti-malarial
activity in the Peters 4-day suppressive test against the
Plasmodium berghei NK65 strain in BALB/c female
mice, each inoculated with 1 × 105 parasitized red blood
cells [28]. The mice were randomly divided into groups
of five individuals and individual groups were treated or-
ally or subcutaneously with 3 or 4 at doses of 50 or
100 mg/kg/day over four days followed by evaluation of
parasitaemia versus controls (negative control groups
were treated with 2% DMSO vehicle and positive control
groups with chloroquine) on days 5 and 7 following an
established procedure [29]. Mortality was monitored in
all groups for four weeks after inoculation. Two inde-
pendent in vivo experiments were performed.
Cytotoxicity assay
The MRC-5 cell line of human fibroblasts was grown in
Dulbecco’s Modified Eagle’s Medium (DMEM) supple-
mented with 10% fetal bovine serum, 2 mM glutamine,100 μg/mL streptomycin and 100 U/mL penicillin, and in-
cubated at 37°C with a 5% atmosphere of CO2. For assays,
the cells were plated in 96-well plates (2.5 × 104 cells/well)
and the AlamarBlue™ assay was performed using a previ-
ously described procedure [30,31]. After incubation for
24 h, compounds 1-5 were individually dissolved in DMSO
and the resulting solutions were diluted in culture medium.
The resulting dilute solutions of each sample were added to
wells at final (well) concentrations of 1.56-100 μg/mL. Con-
trol groups had final well concentrations of 0.1% DMSO.
The plates were further incubated for 48 h. 3 h before the
end of the incubation period, AlamarBlue™ (10 μL) was
added to each well. The fluorescent signal was monitored
with a multiplate reader using 530-560 nm excitation and
590 nm emission wavelengths.
Results
Isolated and semi-synthetic limonoids 1-5 were fully char-
acterized by high-resolution mass spectrometry (HRMS)
and nuclear magnetic resonance (NMR) one and two-
dimensional spectrometric techniques. Comparison of the
NMR spectral data with literature data and analysis of the
1D and 2D NMR data allowed for the positive identification
and spectral assignment of isolated limonoids 1 [32], 2 [33],
3 [34] and 4 [35] (Figure 1). Di-deacetylation of 3 led to the
formation of a product that exhibited HRMS, 1H and 13C
NMR data consistent with 6α-hydroxydeacetylgedunin (5).
Compound 5 has been reported previously, however, no
NMR data were provided [36].
Median inhibitory concentrations (IC50) of com-
pounds 1-5 against P. falciparum K1 strain in vitro are
summarized in Table 1. The IC50 values for these 5
compounds were in the range 5.0-20.7 μM. Semi-
synthetic derivative 5 exhibited the most inhibitory ac-
tivity. The in vitro anti-plasmodial activity of the other
limonoids was moderate. The natural product 4 exhib-
ited the least activity of all limonoids in vitro. Com-
pounds 1-5 were not considered toxic to MRC-5 cells
(4 exhibited an IC50 = 47.3 μg/mL, all other IC50 values
were > 100 μg/mL) over a period of 48 h.
6α-acetoxygedunin (3) and 7-deacetoxy-7-oxogedunin
(4) were each isolated on several hundred milligram scales
which permitted further evaluation of these compounds in
a rodent malaria model. The results of the suppressive test
against P. berghei NK65 in infected mice are presented in
Table 2. In general, limonoid 3 exhibited greater in vivo ac-
tivity than 4. The greatest in vivo activity (65.7% suppres-
sion of parasitaemia as compared to untreated controls)
was observed for 3 administered orally at doses of 100 mg/
kg/day. At a given dose and 5 or 7 days after infection, oral
administration of 3 in general led to greater parasite sup-
pression than did subcutaneous injection of this compound.
Both oral and subcutaneous administration of 4 led to a
suppression of parasitaemia in a clear dose–response. Mice
Table 1 In vitro IC50 values for limonoids from Carapa guianensis against Plasmodium falciparum and human fibroblasts
Plasmodium falciparum K1 Human fibroblasts MRC-5
Limonoids MW IC50 (μM) Result IC50 (μM) SI
6α-acetoxyazadiradione (1) 524 15.4 MA >191 >12
andirobin (2) 492 15.3 MA >203 >13
6α-acetoxygedunin (3) 540 7.0 MA >185 >26
7-deacetyl-7-oxogedunin (4) 438 20.7 I 108 (87.2–134) 5
6α-hydroxydeacetylgedunin (5) 456 5.0 A >219 >44
chloroquine diphosphate 516 0.33 A
quinine sulfate 783 0.30 A
Notes: IC50 ≤ 0.1 μM= highly active; 0.1 < IC50 ≤ 5 μM= active (A); 5 < IC50 ≤ 20 μM=moderately active (MA); IC50 > 20 μM= inactive (I). Selectivity index (SI) = IC50
(human fibroblasts)/IC50 (P. falciparum).
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3 days) at oral doses of 100 mg/kg/day, however, these data
were not statistically significant (T-test p > 0.05 compared
to controls).Discussion
Gedunin (6) has been isolated previously from different
parts of Carapa guianensis and exhibits in vitro activity
(IC50 = 0.40–2.5 μM) against W2, D6 and FCR-3 strains
of P. falciparum [20-22]. However, gedunin (6) was not
isolated in the present work from RPSM. Interestingly, a
recent study on the fruit from the same tree specimens
from which fruit for the present study was collected de-
scribed the isolation of 7-deacetyl gedunin (9), but not
gedunin (6) [35]. Gedunin was considered to be an opti-
mal structure for its high in vitro activity against different
strains of P. falciparum and because structural modifica-
tion of gedunin through semi-synthetic reactions yielded
derivatives exhibiting decreased in vitro anti-plasmodial
activity compared to gedunin [21,22]. This previous work
contributed to a partial understanding of structure-activity
relationships for the in vitro anti-plasmodial activity of
simple gedunin derivatives.Table 2 In vivo suppression of Plasmodium berghei NK65 in m
Dose (mg/kg/day) % Parasite inhibition
Oral Sub
5th day 7th day 5th
6α-acetoxygedunin (3)
100 65.7 46.3 44.2
50 40.2 34.7 34.4
7-deacetoxy-7-oxogedunin (4)
100 40.3 28.9 38.6
50 19.3 0 29.2
chloroquine diphosphate
5 100 98 99
control 0 0 0According to previous reports, deacetylation of gedu-
nin (6) produced compound 9 that exhibited about 65
times less in vitro activity (IC50 = 2.6 and 1.3 μg/mL
against D6 and W2, respectively) than gedunin [21] and
the in vitro activity of 7-O-methyl-deacetylgedunin (10)
and deacetylgedunin (9) are reported to be similar [22].
Based on these and other findings, it was presumed that
the presence of a 7α-acetoxy moiety in the gedunin skel-
eton was important for in vitro anti-plasmodial activity.
Recently, the in vitro activity of limonoids 3 (IC50 =
2.8 μM) and 7 (IC50 = 4.0 μM) was reported against the
FCR-3 strain of P. falciparum [20]. Both of these com-
pounds exhibit a 6α-acetoxy moiety (however, only 3 ex-
hibits a 7α-acetoxy moiety). Thus, a 7α-acetoxy group was
not required for significant in vitro anti-plasmodial activity
against P. falciparum as was thought to be the case for
gedunin (6) itself. However, the low in vitro activity of
gedunin derivative 8 (IC50 = 90 μM) was attributed to the
presence of a 6α-hydroxy group [20]. Herein, the in vitro
anti-plasmodial activity of 5 was reported for the first time
and was shown to be greater than that of the natural iso-
lates 1-4 against the K1 strain of P. falciparum (IC50 =
5.0 μM). Thus, in vitro anti-plasmodial data from previous
reports on 3, 7 and 8 and data generated herein for 6α-ice by limonoids isolated from Carapa guianensis
Average survival time ± SD (day)
cutaneous Oral Subcutaneous
day 7th day
30.4 24 ± 3 22 ± 4
16.8 20 ± 3 21 ± 2
21.7 21 ± 3 22 ± 2
0 20 ± 2 21 ± 4
99 >40 >40
0 21 ± 2 21 ± 3
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consistent with the notion that within this group of gedunin
derivatives, an O-acetyl group at the 6 and/or 7 position is
not a requirement for significant in vitro anti-plasmodial
activity against P. falciparum.
6α-acetoxygedunin (3) has been isolated previously
from the flowers of Carapa guianensis and exhibited an
IC50 = 2.8 μM against the FCR-3 strain of P. falciparum
[20]. Herein, 3 was the most active of the isolates from
RPSM and exhibited an IC50 = 7.0 μM against the K1
strain of P. falciparum. Limonoid 1 was half as active
in vitro as 3, in good agreement with previously pub-
lished data and an indication of the modulation of
in vitro activity caused by structural changes to ring D
[20]. The in vitro activity of limonoid 3 and its availabil-
ity on a larger scale by isolation from RPSM led us to
further explore its anti-malarial potential in P. berghei-
infected mice.
7-deacetoxy-7-oxogedunin (4) has been isolated previ-
ously from two species of Meliaceae, Carapa guianensis
[20,21] and Pseudocedrela kotschyi [37], and tested for
in vitro anti-plasmodial activity against several strains of
P. falciparum. In earlier studies, 4 exhibited in vitro ac-
tivity against the K1 and FCR-3 strains of P. falciparum
(IC50 = 2.5-4.1 μM) [20,37]. However, herein, we found 4
to be relatively inactive against the K1 strain of P. falcip-
arum (IC50 = 20.7 μM). Similarly, a previous report
found 4 to be inactive against the W2 strain of P. falcip-
arum (IC50 > 22.8 μM) [21]. Parasite strain specificity
and/or variability of the anti-plasmodial response may
be responsible for the mixed in vitro results obtained
herein and elsewhere for 4. We were thus induced to try
to shed new light on the anti-malarial potential of 4 by
further studying its activity in P. berghei-infected mice.
Herein, andirobin (2), a seco-gedunin, exhibited mod-
erate in vitro anti-plasmodial activity (IC50 = 15.3 μM).
In other work, a 7,8-seco-gedunin andirobin-like com-
pound having an acetyl function instead of the furan
ring and otherwise structurally analogous to 2, as well as
the 7,8-seco-gedunin, methyl angolensate, were found to
have quite similar in vitro activities (IC50 = 12–15 μM)
against the FCR-3 strain of P. falciparum [20]. Thus, an in-
tact B ring may be important for optimal in vitro activity of
gedunin derivatives against P. falciparum, and modification
of the stereochemistry and type of substituent on the B ring
at the 6 and 7 positions (e.g. of derivative 5), could be an
important strategy for optimizing the anti-plasmodial activ-
ity of gedunin derivatives.
Herein, 6α-acetoxygedunin (3) and 7-deacetoxy-7-oxoge-
dunin (4) administered orally at doses of 50 and 100 mg/
kg/day (Table 2), respectively, to P. berghei strain NK65-
infected mice exhibited comparable in vivo anti-malarial ac-
tivity (40% parasitemia suppression compared to untreated
controls) to that reported previously by others for thenatural isolate gedunin (6) at doses of 50 mg/kg/day in P.
berghei strain ANKA-infected mice. Also, 6 reportedly did
not suppress P. berghei in mice at oral doses of 25 or
100 mg/kg/day and thus did not exhibit dose–response
[22]. However, herein, 3 administered orally at 100 mg/kg/
day exhibited 66% suppression of parasitaemia of P. berghei
on day 5 showing a dose–response pattern (and greater
in vivo suppression of parasitemia than gedunin at this
same dose). Comparable in vivo suppression of P. berghei
to that of gedunin and clear dose–response highlight the
potential of natural 6-substituted gedunin derivative 3.
While experience varies, substances exhibiting 30 to 40%
in vivo parasitaemia suppression in mouse malaria models
are considered to be moderately active whereas suppres-
sion ≥40% at the doses tested herein is associated with ac-
tive anti-malarial compounds [38-40]. The present study
was conducted with pure bred BALB/c mice infected with
P. berghei, a reliable model that is similar to that used in
the identification of drug candidates MK-4815, NITD609
and OZ439 that are now in clinical trials [41,42].
Despite several studies on the in vitro anti-plasmodial
activity of limonoids related to gedunin as discussed
above, previous in vivo anti-malarial studies on gedunin
derivatives were limited to gedunin (6) [22,23,43] and
the semi-synthetic compound 10 [22]. The low oral ac-
tivity of gedunin was attributed to low absorption and
instability under physiologic conditions led to the semi-
synthesis of deacetylgedunin (9). Compound 9 was un-
stable under physiologic conditions found in mice (and
presumably in humans) [23]. For this reason, the 7-
hydroxy group of compound 9 was methylated to provide
7-methoxy gedunin 10. Compound 10 administered orally
at doses of 50 mg/kg/day inhibited parasitaemia of P. ber-
ghei ANKA in mice by 68% [22] which is in vivo suppres-
sion of parasitaemia comparable to that observed herein
for orally-administered isolate 3 at 100 mg/kg/day against
P. berghei NK65 (Table 2).
It is important to keep in mind that highly potent
and clinically useful anti-malarials were often discov-
ered in plant materials or are derived from plant nat-
ural products used directly by humans as part of
traditional practice. Often, however, clinically useful
anti-malarials provide results that are not optimal for
treatment of rodent malaria. Thus, quinine which was
the basis for malaria treatment and prophylaxis in the
19th and early 20th centuries, exhibits a median effect-
ive dose (ED50) of 34 mg/kg/day in mice infected with
P. berghei strain ANKA [44] and Plasmodium vinckei-
infected mice exhibit recrudescence when treated with the
artemisinin derivative sodium artesunate at doses <80 mg/
kg/day [45]. Thus, the significant in vivo anti-malarial ac-
tivity exhibited by limonoid natural product 3 has moti-
vated to us to investigate the anti-malarial potential of
its derivatives.
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or O-acyl groups in the 6 and 7 positions should be in-
vestigated. O-derivatization of the 7α-hydroxy group in
5 may be important for chemical stability and in vivo
anti-malarial activity given the structural analogy of 5
with 7-deacetyl gedunin (9) and the low in vivo anti-
malarial activity of the latter compound. The low sta-
bility of 9 under simulated gastric (low pH) conditions
was shown to be due to B ring-opening provoked by
the intrinsic reactivity of the 7α-hydroxy moiety [23].
Thus, O-alkylation or O-acylation with a sterically hin-
dered ester group on the 7α-hydroxy (and 6α-hydroxy)
group of 5 should be investigated as a means to gener-
ate novel substances for in vitro and in vivo study of
anti-malarial activity and could lead to a better under-
standing of the effects of B ring substituents on the sta-
bility and anti-malarial activity of gedunin derivatives.
Conclusions
Today, in the fight against malaria, the clinically most
relevant anti-malarials, synthetic quinolines and semi-
synthetic artemisinin derivatives, owe their origins to
the natural products quinine and artemisinin, respect-
ively, found in traditionally-used plants. Furthermore,
medicinal plants selected through the ethnopharmaco-
logic approach are proving to be important sources of
drugs introduced in the past decades. Thus, limonoids
1-4 were isolated from C. guianensis waste seed mate-
rials and their in vitro efficacy against P. falciparum and
cytotoxicity to normal cells was evaluated. Limonoids
3 and 4 were further evaluated in vivo against P. ber-
ghei in mice. Our in vitro and in vivo results were con-
textualized within what is known on the inhibitory
activity of gedunin derivatives from previous studies.
6α-acetoxygedunin (3) was shown herein to exhibit
significant in vivo anti-malarial activity and dose–re-
sponse that make this natural derivative of gedunin a
rival to gedunin (6) itself as a model structure for fur-
ther investigation. Future work will focus on the
in vitro and in vivo activity of 6 and 7-substituted de-
rivatives of semi-synthetic limonoid 5. Also, as a means
to avoid monotherapy and to enhance in vivo anti-
malarial activity, studies are planned on the potential syn-
ergism of 3 and derivatives of 5 with dillapiole, a natural
product known to strongly inhibit cytochrome P450 and
significantly enhance the in vivo anti-malarial activity of
gedunin (6) and gedunin derivative 10 according to a pre-
vious study in a mouse malaria model [22].
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